Carlyle-backed Indegene clocks 26% gain on stock market debut
Indegene Ltd, a technology-led healthcare solutions provider to biopharmaceutical, biotech and medical devices companies, made a strong stock market debut on Monday with its shares gaining 26.25% on the first day of trade. Shares of Indegene, backed by private equity firm Carlyle, listed on BSE Ltd at Rs 659.70 apiece, up 46% ......
Carlyle-backed Indegene’s IPO gets bumper response; Aadhar Housing, TBO Tek make slow start
Three companies that are backed by private equity investors hit the market this week, with two launching their bids on Wednesday and one seeing a spectacular response from investors on the final day. Indegene Ltd, backed by Carlyle and Nadathur Holdings, recorded subscription of 69.66 times the shares on offer. It ......
Carlyle-backed Indegene makes another overseas acquisition
Indegene, a technology-led healthcare solutions provider to biopharmaceutical, biotech and medical devices companies, has acquired another overseas company to ramp up its service offerings. The Indian company, which is backed by US-based private equity firm Carlyle, has purchased medical writing consultancy firm Trilogy Writing & Consulting GmbH. Indegene said in a statement Trilogy's acquisition will ......
Deals Digest: Funding momentum slows further in shorter week
Capital raised by private equity and venture capital-backed startups slipped for the second consecutive week, as overall activity was subdued due to a three-day working week on account of Holi and Good Friday holidays. Overall funding raised by startups and companies backed by altrnative investors nearly halved this week to $236 ......
Indegene, Mamaearth parent get SEBI approval for IPO
Private equity and venture capital-backed firms Indegene, a pharma player and skincare brand Mamaearth’s parent Honasa Consumer have received approval from Securities and Exchange Board of India (Sebi) for their respective initial public offerings. Both companies had filed preliminary papers with the market regulator in December 2022, with an aim to ......
Carlyle makes a partial exit from IPO-bound Indegene
Private equity firm Carlyle has trimmed its stake in Indegene, just two years after teaming up with another investment firm to joint betting $200 million (Rs 1,500 crore then) on the healthtech venture. Carlyle had joined hands with Brighton Park Capital, a private investment firm that focuses on software, information services, ......
Carlyle, two others to pare stakes in Indegene via IPO route
US private equity giant Carlyle and two other investors are planning to make partial exits from Indegene Ltd through an initial share sale of the technology-led healthcare solutions provider worth up to ₹3,200 crore. Carlyle along with Brighton Park Capital and the Nadathur Family Office are proposing to sell less than ......
Silence Laboratories, four others raise early-stage funding
Privacy-tech startup Silence Laboratories, software-as-a-service (SaaS) startups Zvolv and Nurturev, construction material marketplace Bandhoo, and ambulance service provider Dial4242 raised early-stage funding, the companies said on Thursday. Silence Laboratories Silence Laboratories has raised $4.1 million (Rs 34 crore) in a pre-Series A funding round led by Pi Ventures. The round ......
Bourse-bound Indegene buys New York’s marketing firm CultHealth
Bengaluru-based Indegene Lifesystems Pvt Ltd, which provides clinical, commercial and marketing solutions to life sciences and pharmaceutical companies, has bought New York-based healthcare marketing agency CultHealth through its subsidiary ILSL Inc. However, the company did not disclose the size of the acquisition. With this buyout, Indegene will look to improve its portfolio ......
